Supplemental material

Desmond Curran, Joon Hyung Kim, Sean Matthews, Christophe Dessart, Myron J. Levin, Lidia Oostvogels, Megan E. Riley, Kenneth E. Schmader, Anthony L. Cunningham, Shelly A. McNeil, Anne E. Schuind, Melissa K. Andrew, on behalf of the Zoster-064 Study Group. *Recombinant Zoster Vaccine is Efficacious and Safe in Frail Individuals.* Journal of the American Geriatrics Society.

Supplemental File S1 - Frailty Assessment

Supplementary Table S1 - Details of components of frailty index

Supplementary Table S2 - Detail of medical history search items

Supplementary Table S3 - Vaccine efficacy estimates (modified total vaccinated cohort)

Supplementary Table S4 - Number of participants in the various cohorts (total vaccinated cohort)

Supplementary Table S5 - Summary of demographic characteristics

Supplementary Table S6 - Incidence and nature of symptoms (solicited only) reported during the 7-day (days 0–6) post-vaccination period overall per participant by frailty status (total vaccinated cohort - diary card subset)

Supplementary Figure S1 - Percentages of participants reporting any unsolicited adverse events within the 30-day (days 0-29) post-vaccination by frailty status (total vaccinated cohort)

Supplemental File S1 - Frailty assessment

The frailty index (FI) was scored between 0 and 41 as detailed in Supplementary Table S1. The subject's prevaccination questionnaires contributed a max score of 29 and the medical history contributed a max score of 12. If a participant had more than 10 missing quality of life components, the FI was treated as missing, unless based on their available data their classification as frail was unquestionable (they already had sufficient deficits to be classified as frail).

The medical history was divided into 12 selected deficits (Supplementary Table S2). The coded combined medical history database from studies ZOE-50 and ZOE-70 were searched and participants with the relevant preferred terms were assigned to 1 or more of the deficits. If a subject had any of the listed events in a deficit category, they were assigned a max score of 1 for that deficit.

Item	Scoring method based on response to questionnaire or medical history assessment	Max Contribution to Frailty Index
SF-36 Q1	Poor=1	1
	Fair=0.5	
	Good=0	
	Very good=0	
	Excellent=0	
SF-36 Q11A-11D	Q11A, Q11C	4
	Definitely true=1	
	Mostly true=0.5	
	Don't know=0	
	Mostly false=0	
	Definitely false=0	
	Q11B, Q11D	
	Definitely true=0	
	Mostly true=0	
	Don't know=0	
	Mostly false=0.5	
	Definitely false=1	
SF-36 Q3A - Q3J	Limited a lot=1	10
	Limited a little=0.5	
	Not limited at all=0	
SF-36 Q9A - Q9I	Q9A, Q9D, Q9E, Q9H	9
	All of the Time=0	
	Most of the time=0	
	Some of the time=0	
	A little of the time=0.5	
	None of the time=1	
	Q9B, Q9C, Q9F, Q9G, Q9I	
	All of the time=1	
	Most of the time=0.5	
	Some of the time=0	
	A little of the time=0	
	None of the time=0	
F-36 Q2	Much worse=1	1
-	Somewhat worse=0.5	
	Same=0	
	Somewhat better=0	
	Better=0	
EQ-5D Mobility	No Problems=0	1
- <u>z</u>	Some Problems=0.5	
	Confined to bed=1	
EQ-5D Anxiety	No Anxiety=0	1
	Moderate Anxiety=0.5	-
	Extreme Anxiety=1	
EQ-5D Self care	No Problems=0	1
	Some Problems=0.5	-
	Inability to wash or dress himself /herself=1	
EQ-5D Usual activities	No Problems=0	1
	Some Problems=0.5	-
	Inability to perform usual activities=1	
Medical history	Cancer	1
inconcent instory	Diabetes Mellitus	1
	High Blood Pressure	1
	Heart Attack	1
	Congestive Heart Failure	1
	Cerebrovascular Disease	1
	Arthritis	1
	Chronic Lung Disease	1
		1
	Stomach or Intestinal Ulcers	1
	Migraine	1
	Cataract	1
	Glaucoma	<u> </u>

Supplementary Table S1 - Details of components of frailty index

EQ-5D=EuroQol-5 Dimension; Q=question; SF-36=Short Form Survey-36

Supplementary Table S2 - Detail of medical history search items

Deficit	MedDRA version 18 Search Terms
Cancer	Malignancy related conditions (SMQ)
	Malignant tumours (SMQ)
Diabetes Mellitus	Diabetes mellitus (incl subtypes) (HLT)
	Diabetic complications (HLGT)
High Blood Pressure	Hypertension (SMQ)
Heart Attack	Ischaemic heart disease (SMQ)
Congestive Heart Failure	Cardiac failure (SMQ)
Cerebrovascular Disease	Central nervous system vascular disorders (SMQ)
Arthritis	Arthritis (SMQ)
Chronic Lung Disease	Asthma/bronchospasm (SMQ)
-	Interstitial lung disease (SMQ)
	Pulmonary hypertension (SMQ)
	Chronic Obstructive Pulmonary Disease (PT) / Infective exacerbation of chronic obstructive airways diseas
	(PT)
	Bronchiectasis (PT) / Infective exacerbation of bronchiectasis (PT)
	Cystic fibrosis (PT) / Cystic fibrosis lung (PT) / Infective pulmonary exacerbation of cystic fibrosis (PT)
	Chronic respiratory disease (PT)
	Chronic respiratory failure (PT)
Stomach or Intestinal	Gastrointestinal ulceration (SMQ)
Ulcers	
Migraine	Migraine headaches (HLT)
0	Migraine prophylaxis (PT)
Cataract	Cataract Conditions (HLT)
	Cataract operation (PT)
	Cataract diabetic (PT)
	Cataract operation complication (PT)
Glaucoma	Glaucoma (SMQ)

HLGT=high level group term; HLT=high level term; PT=preferred term; SMQ=Standardized MedDRA queries

Herpes zoster			RZV group	1			Vaccine Efficacy		
	N	n	T (year)	n/T (per 1000)	Ν	n	T(year)	n/T (per 1000)	% (95% CI)
Non-Frail	5545	8	21803	0.4	5551	188	21443	8.8	95.8 (91.6, 98.2)
Pre-Frail	5738	18	21842	0.8	5969	191	22250	8.6	90.4 (84.4, 94.4)
Frail	1449	5	5158	1.0	1348	46	4663	9.9	90.2 (75.4, 97.0)
Unknown	53	0	186	0.0	62	5	194	25.8	100.0 (14.6, 100.0)
Burden of Illness		RZV group				Vaccine Efficacy			
	N	n	T (year)	ZBPI BOI	Ν	n	T (year)	ZBPI BOI	% (95% CI)
Non-Frail	5545	8	21803	0.017	5550	187	21439	1.173	98.6 (97.1, 100.0)
Pre-Frail	5738	18	21842	0.108	5968	190	22248	1.475	92.6 (86.6, 98.7)
Frail	1449	5	5158	0.345	1348	46	4663	2.330	85.2 (62.6, 100.0)
Unknown	53	0	186	0.000	60	3	190	3.303	100.0 (NE)

Supplementary Table S3 - Vaccine efficacy estimates (modified total vaccinated cohort)

N=number of participants with follow-up; n=number of participants with a confirmed zoster episode; RZV=adjuvanted recombinant zoster vaccine; T (year)=total years of follow-up for all participants in that subgroup; 95% CI=95% confidence interval using the variance estimate of the vaccine efficacy from the Chang test; ZBPI=Zoster Brief Pain Inventory; BOI=burden of illness; NE=not estimable

"Unknown" refers to participants who could not be assigned a frailty subgroup due to missing data

ZBPI Burden of Illness score was calculated as the sum of the ZBPI worst pain scores for all participants in the group divided by participant years of follow-up. Participants who did not have a confirmed zoster episode were assigned a score of 0. Four participants in the placebo group who had a confirmed zoster episode but who did not have at least one ZBPI assessment were excluded from the analysis of ZBPI BOI efficacy

Supplementary Table S4 - Number of participants in the various cohorts (total vaccinated cohort)

	RZV N=13487	Placebo N=13489	Total N=26976
	n	n	n
Total vaccinated cohort	13487	13489	26976
Modified total vaccinated cohort	12785	12930	25715
Total vaccinated cohort - diary card subset	4570	4571	9141
ATP cohort for immunogenicity - humoral month 3	1400	1432	2832
ATP cohort for immunogenicity - humoral month 14	1360	1366	2726
ATP cohort for immunogenicity - humoral month 26	1318	1314	2632
ATP cohort for immunogenicity - humoral month 38	1255	1253	2508
ATP cohort for immunogenicity - CMI month 3	196	204	400
ATP cohort for immunogenicity - CMI month 14	187	194	381
ATP cohort for immunogenicity - CMI month 26	185	188	373
ATP cohort for immunogenicity - CMI month 38	174	180	354

ATP=according-to-protocol; CMI=cell-mediated immunogenicity; N=total number of participants; n=number of participants in the given cohort=RZV, adjuvanted recombinant zoster vaccine

		RZV	Placebo	Total
		N=13487	N=13489	N=26976
Age (years)				
	Mean	68.8	68.8	68.8
	Median	71.0	71.0	71.0
	Minimum	50	48	48
	Maximum	96	95	96
Gender	Female	58.0 %	58.3 %	58.1 %
	Male	42.0 %	41.7 %	41.9 %
Ethnicity				
-	American hispanic or latino	8.8 %	8.8 %	8.8 %
	Not american hispanic or latino	91.2 %	91.2 %	91.2 %
Geographic Ancestry	L.			
	White - Caucasian / European	74.6 %	74.5 %	74.6 %
	Heritage			
	Asian - East Asian Heritage	15.2 %	15.1 %	15.2 %
	Other	4.7 %	4.8 %	4.8 %


Supplementary Table S5 - Summary of demographic characteristics


N=total number of participants; RZV=adjuvanted recombinant zoster vaccine

			Any symptom						Local symptoms								
	Sub-group					95%	5 CI				95%	6 CI				95%	% CI
		Group	Ν	n	%	LL	UL	Ν	n	%	LL	UL	Ν	n	%	LL	UL
Any Grade	Non-Frail	RZV	2008	1752	87.3	85.7	88.7	2007	1369	68.2	66.1	70.2	2007	1699	84.7	83.0	86.2
		Placebo	2034	654	32.2	30.1	34.2	2034	558	27.4	25.5	29.4	2034	227	11.2	9.8	12.6
	Pre-Frail	RZV	1977	1649	83.4	81.7	85.0	1971	1242	63.0	60.8	65.1	1977	1559	78.9	77.0	80.6
		Placebo	1964	662	33.7	31.6	35.8	1964	575	29.3	27.3	31.3	1964	227	11.6	10.2	13.1
	Frail	RZV	490	360	73.5	69.3	77.3	488	248	50.8	46.3	55.3	489	335	68.5	64.2	72.6
		Placebo	468	169	36.1	31.8	40.6	468	154	32.9	28.7	37.4	468	51	10.9	8.2	14.1
	Unknown	RZV	21	18	85.7	63.7	97.0	21	11	52.4	29.8	74.3	21	17	81.0	58.1	94.6
		Placebo	18	7	38.9	17.3	64.3	18	6	33.3	13.3	59.0	17	2	11.8	1.5	36.4
Grade 3	Non-Frail	RZV	2008	349	17.4	15.7	19.1	2007	240	12.0	10.6	13.5	2007	190	9.5	8.2	10.8
		Placebo	2034	37	1.8	1.3	2.5	2034	36	1.8	1.2	2.4	2034	4	0.2	0.1	0.5
	Pre-Frail	RZV	1977	279	14.1	12.6	15.7	1971	185	9.4	8.1	10.8	1977	172	8.7	7.5	10.0
		Placebo	1964	44	2.2	1.6	3.0	1964	40	2.0	1.5	2.8	1964	6	0.3	0.1	0.7
	Frail	RZV	490	75	15.3	12.2	18.8	488	50	10.2	7.7	13.3	489	50	10.2	7.7	13.3
		Placebo	468	24	5.1	3.3	7.5	468	22	4.7	3.0	7.0	468	5	1.1	0.3	2.5
	Unknown	RZV	21	1	4.8	0.1	23.8	21	0	0.0	0.0	16.1	21	1	4.8	0.1	23.8
		Placebo	18	0	0.0	0.0	18.5	18	0	0.0	0.0	18.5	17	0	0.0	0.0	19.5

Supplementary Table S6 - Incidence and nature of symptoms (solicited only) reported during the 7-day (days 0–6) post-vaccination period overall per participant by frailty status (total vaccinated cohort - diary card subset)

CI=confidence interval; LL=lower limit; N=number of participants in each group; n (%)=number (percentage) of participants reporting the adverse event at least once; RZV=adjuvanted recombinant zoster vaccine; UL=upper limit





RZV= adjuvanted recombinant zoster vaccine